AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?

Amgen is trading above key simple moving averages as strong drug sales and momentum in the MariTide pipeline, along with resilience around biosimilars, offset looming patent expirations and pricing headwinds. The net picture is mildly positive for the stock’s technical and fundamental outlook, but patent losses and pricing pressure remain material downside risks to revenue and margins over the medium term.

Analysis

Amgen is trading above key simple moving averages as strong drug sales and momentum in the MariTide pipeline, along with resilience around biosimilars, offset looming patent expirations and pricing headwinds. The net picture is mildly positive for the stock’s technical and fundamental outlook, but patent losses and pricing pressure remain material downside risks to revenue and margins over the medium term.